RedHill Biopharma (RDHL) Misses Q2 EPS by 4c
Get Alerts RDHL Hot Sheet
Join SI Premium – FREE
RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $23.19 million.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Eledon Pharmaceuticals, Inc. (ELDN) Tops Q4 EPS by 4c
- Volcon (VLCN) Reports 2023 Operational and Financial Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!